Newron Pharmaceuticals 将来の成長

Future 基準チェック /66

Newron Pharmaceuticals利益と収益がそれぞれ年間45.2%と33.9%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に49% 44.7%なると予測されています。

主要情報

45.2%

収益成長率

44.75%

EPS成長率

Pharmaceuticals 収益成長	12.2%
収益成長率	33.9%
将来の株主資本利益率	49.04%
アナリストカバレッジ	Low
最終更新日	02 Oct 2025

今後の成長に関する最新情報

Earnings Miss: Newron Pharmaceuticals S.p.A. Missed EPS By 53% And Analysts Are Revising Their Forecasts

Apr 05

Recent updates

Newron Pharmaceuticals S.p.A. (VTX:NWRN) Soars 29% But It's A Story Of Risk Vs Reward

Sep 30

Take Care Before Diving Into The Deep End On Newron Pharmaceuticals S.p.A. (VTX:NWRN)

Aug 12

Newron Pharmaceuticals (NWRN) – Binary CNS Bets with 3-to-1 Upside

Jul 081. Catalysts Evenamide (Schizophrenia Add-On Therapy): The key growth catalyst for Newron is Evenamide, a novel glutamate-modulating drug in Phase III development for treatment-resistant schizophrenia (TRS).

Earnings Miss: Newron Pharmaceuticals S.p.A. Missed EPS By 53% And Analysts Are Revising Their Forecasts

Apr 05

Take Care Before Jumping Onto Newron Pharmaceuticals S.p.A. (VTX:NWRN) Even Though It's 29% Cheaper

Apr 03

Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) Price In Tune With Revenues

Sep 03

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Apr 11

We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

Nov 06

Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Apr 06

Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

Apr 01

A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

Feb 25

業績と収益の成長予測

SWX:NWRN - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	74	40	52	53	2
12/31/2026	43	4	37	38	3
12/31/2025	23	-16	32	33	3
6/30/2025	60	25	25	25	N/A
3/31/2025	56	21	3	3	N/A
12/31/2024	51	16	-18	-18	N/A
9/30/2024	29	-1	-16	-15	N/A
6/30/2024	7	-19	-13	-13	N/A
3/31/2024	8	-18	-12	-12	N/A
12/31/2023	9	-16	-10	-10	N/A
9/30/2023	9	-16	-11	-11	N/A
6/30/2023	9	-16	-11	-11	N/A
3/31/2023	7	-17	-11	-11	N/A
12/31/2022	6	-17	-11	-11	N/A
9/30/2022	6	-16	-10	-10	N/A
6/30/2022	6	-14	-8	-8	N/A
3/31/2022	6	-15	-10	-10	N/A
12/31/2021	6	-15	-11	-11	N/A
9/30/2021	6	-17	-14	-14	N/A
6/30/2021	5	-20	-17	-17	N/A
3/31/2021	5	-20	-16	-16	N/A
12/31/2020	5	-21	-16	-16	N/A
9/30/2020	6	-19	-15	-15	N/A
6/30/2020	7	-17	-14	-14	N/A
3/31/2020	7	-18	-18	-18	N/A
12/31/2019	7	-20	-22	-22	N/A
9/30/2019	6	-21	-22	-22	N/A
6/30/2019	4	-21	-21	-21	N/A
3/31/2019	4	-18	N/A	-19	N/A
12/31/2018	4	-15	N/A	-16	N/A
9/30/2018	4	-15	N/A	-16	N/A
6/30/2018	4	-14	N/A	-16	N/A
3/31/2018	9	-10	N/A	-12	N/A
12/31/2017	13	-5	N/A	-8	N/A
9/30/2017	14	-5	N/A	-10	N/A
6/30/2017	15	-5	N/A	-12	N/A
3/31/2017	11	-10	N/A	-16	N/A
12/31/2016	7	-15	N/A	-20	N/A
9/30/2016	6	-20	N/A	-18	N/A
6/30/2016	4	-25	N/A	-17	N/A
3/31/2016	3	-24	N/A	-15	N/A
12/31/2015	2	-23	N/A	-13	N/A
9/30/2015	2	-18	N/A	-12	N/A
6/30/2015	2	-12	N/A	-11	N/A
3/31/2015	2	-11	N/A	-10	N/A
12/31/2014	2	-10	N/A	-10	N/A

アナリストによる今後の成長予測

収入対貯蓄率: NWRNの予測収益成長率 (年間45.2% ) は貯蓄率 ( 0.5% ) を上回っています。

収益対市場: NWRNの収益 ( 45.2% ) はSwiss市場 ( 10.3% ) よりも速いペースで成長すると予測されています。

高成長収益: NWRNの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: NWRNの収益 ( 33.9% ) Swiss市場 ( 3.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: NWRNの収益 ( 33.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NWRNの自己資本利益率は、3年後には非常に高くなると予測されています ( 49 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/11/19 20:49
終値	2025/11/19 00:00
収益	2025/06/30
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Newron Pharmaceuticals S.p.A. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。7

アナリスト	機関
Thomas Meyer	Baader Helvea Equity Research
Jyoti Prakash	Edison Investment Research
Lucy Codrington	Jefferies LLC

Newron Pharmaceuticals 将来の成長

Future 基準チェック /66

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 13%

Consensus EPS estimates fall by 45%, revenue upgraded

Earnings Miss: Newron Pharmaceuticals S.p.A. Missed EPS By 53% And Analysts Are Revising Their Forecasts

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2026

Recent updates

Newron Pharmaceuticals S.p.A. to Present New Analyses From and Updates on its Clinical Program Evaluating Evenamide as an Add-On Treatment for Schizophrenia at the 38th European College of Neuropsychopharmacology (ECNP) Congress 2025

Investor sentiment improves as stock rises 22%

Newron Pharmaceuticals S.p.A. (VTX:NWRN) Soars 29% But It's A Story Of Risk Vs Reward

Consensus revenue estimates increase by 13%

Investor sentiment improves as stock rises 17%

Newron Pharmaceuticals S.p.A. Announces Board Changes

Newron Pharmaceuticals S.p.A. to Present Data and Updates on Its Clinical Program Evaluating Evenamide as an Add-On Treatment for Schizophrenia At the 2025 World Congress of Biological Psychiatry

Investor sentiment improves as stock rises 22%

Consensus EPS estimates fall by 45%, revenue upgraded

New major risk - Revenue and earnings growth

Newron Pharmaceuticals S.p.A. Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program with Evenamide as Add-On Therapy in Patients with Treatment-Resistant Schizophrenia (TRS)

Take Care Before Diving Into The Deep End On Newron Pharmaceuticals S.p.A. (VTX:NWRN)

Newron Pharmaceuticals (NWRN) – Binary CNS Bets with 3-to-1 Upside

Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program with Evenamide as Add-On Therapy in Patients with Treatment-Resistant Schizophrenia (TRS)

Investor sentiment improves as stock rises 17%

New major risk - Share price stability

Earnings Miss: Newron Pharmaceuticals S.p.A. Missed EPS By 53% And Analysts Are Revising Their Forecasts

Take Care Before Jumping Onto Newron Pharmaceuticals S.p.A. (VTX:NWRN) Even Though It's 29% Cheaper

Full year 2024 earnings released: EPS: €0.85 (vs €0.91 loss in FY 2023)

New major risk - Financial position

Forecast breakeven date pushed back to 2025

Newron Pharmaceuticals S.p.A. to Report First Half, 2025 Results on Sep 16, 2025

First half 2024 earnings released: €0.52 loss per share (vs €0.39 loss in 1H 2023)

New minor risk - Financial position

Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) Price In Tune With Revenues

Newron Pharmaceuticals S.P.A Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients

Forecast breakeven date pushed back to 2026

Newron Pharmaceuticals S.p.A. Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients

Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Consensus revenue estimates fall by 19%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Forecast breakeven date pushed back to 2025

Newron Reports Exceptional One-Year Results of Study 014/15 with Evenamide in Treatment-Resistant Schizophrenia (TRS)

Newron Pharmaceuticals S.p.A. Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A with Evenamide

Newron Pharmaceuticals S.p.A. to Report Fiscal Year 2023 Results on Mar 19, 2024

Forecast breakeven date pushed back to 2025

Forecast breakeven date moved forward to 2023

Newron Pharmaceuticals S.P.A. Presents New Data from Study 014/015 Evaluating Its Investigational Drug Evenamide for the Management of Treatment Resistant Schizophrenia

Newron Pharmaceuticals S.p.A. Appoints Margarita Chavez as Board Advisor

New minor risk - Market cap size

Forecast breakeven date moved forward to 2023

Full year 2022 earnings released: €0.98 loss per share (vs €0.83 loss in FY 2021)

Newron Reports Striking One-Year Interim Efficacy Results from Its Phase Ii Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients with Treatment-Resistant Schizophrenia

Newron Pharmaceuticals S.p.A. Announces Striking Six-Month Interim Results from Its Exploratory Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients with Treatment-Resistant Schizophrenia

Newron Pharmaceuticals S.p.A., Annual General Meeting, Apr 18, 2023

Insufficient new directors

First half 2022 earnings released: €0.48 loss per share (vs €0.51 loss in 1H 2021)

Newron Pharmaceuticals S.P.A. Presents Encouraging Interim Results for Evenamide in Patients with Treatment-Resistant Schizophrenia (Trs) At the 33Rd Cinp Hybrid World Congress of Neuropsychopharmacology

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

First half 2021 earnings released: €0.51 loss per share (vs €0.59 loss in 1H 2020)

Newron Pharmaceuticals S.p.A. Announces Paragraph IV ANDA Filings for Xadago® (safinamide) in the USA

Newron Pharmaceuticals S.p.A. Announces Paragraph IV ANDA filing for Xadago(R) (safinamide) in the USA

Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

Consensus forecasts updated

Consensus forecasts updated

Full year 2020 earnings released: €1.18 loss per share (vs €1.13 loss in FY 2019)

Newron Pharmaceuticals S.p.A., Annual General Meeting, Apr 13, 2021

Newron and Zambon Sign Agreement for Potentially Pivotal Study with Safinamide in Parkinson’s Disease Patients

New 90-day high: CHF2.99

A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

New 90-day high: CHF2.95

Newron Pharmaceuticals Completes Enrollment of Explanatory Safety and Efficacy Study with Evenamide in Schizophrenia Patients

New 90-day high: CHF2.25

New 90-day high: CHF2.11